· updated
BPC-157: What the Evidence Actually Shows in 2026
BPC-157 (Body Protection Compound-157) is a synthetic peptide derived from a fragment of a protein found in human gastric juice. It’s one of the most searched and most discussed peptides in the recovery and longevity space — largely on the strength of a deep bench of animal research. What’s often left out of that conversation is how thin the human evidence still is, and where the regulatory status actually stands. This is a plain look at both, not a recommendation.
What it is
BPC-157 is a short, stable chain of 15 amino acids, studied since the 1990s primarily in rodent models. Researchers have been interested in it because of its apparent role in angiogenesis (new blood vessel formation) and tissue-repair signaling pathways — mechanisms that would plausibly matter for gut lining, tendons, and muscle if they translate to humans.
What the evidence shows — and where the gaps are
The honest summary: extensive preclinical (animal) evidence, essentially no controlled human evidence.
- A 2025 systematic review of the BPC-157 literature (spanning 1993–2024) identified roughly three dozen studies — and only one was a clinical (human) study; the rest were preclinical, mostly in rodents.
- The one human data point that does exist is a small 2025 IRB-approved safety pilot — two healthy adults given intravenous BPC-157 up to 20 mg, reporting tolerability with no serious adverse events. That’s a safety signal in two people, not an effectiveness study.
- As of early 2026, no completed, peer-reviewed randomized controlled trial of BPC-157 has been published for any human indication, and no actively recruiting trials appear on ClinicalTrials.gov.
- The animal literature does show consistent signals across independent labs in musculoskeletal injury models (tendon, ligament, gut lining) — which is why interest remains high — but consistent animal results are not the same as demonstrated human safety or effectiveness, and don’t reliably predict human dosing, absorption, or long-term risk.
Regulators have flagged specific open questions too: FDA’s own review materials cite adverse-event reports submitted to its FAERS database associated with BPC-157 use, underscoring that real-world safety data in humans remains limited and not systematically collected.
Current regulatory status
BPC-157 is not an FDA-approved drug and has never gone through FDA’s approval process for any use. Its bulk-substance status has moved twice in 2026: it was removed from the FDA’s Category 2 (restricted) compounding list in April 2026, but it has not been added to the Category 1 list that would clearly authorize pharmacy compounding. FDA’s Pharmacy Compounding Advisory Committee reviewed BPC-157 (alongside KPV, TB-500, and MOTS-c) on July 23, 2026 for possible inclusion on the 503A Bulks List; FDA’s own pre-meeting briefing materials reportedly leaned against adding it. The committee voted 8-6 (1 abstention) to recommend it; the vote is advisory and, as of mid-September 2026, FDA had not yet published a proposed rule. For the current, up-to-date status, see our live legal status tracker, and for the full regulatory backstory see is BPC-157 legal in 2026?
What people discuss with providers
Given the state of the evidence, conversations with licensed providers about BPC-157 tend to center on: what the animal data does and doesn’t tell us, what a provider considers an acceptable evidence bar before recommending anything off-label, what is and isn’t currently compoundable, and how a provider weighs unknowns like long-term safety and interaction risk. None of that is a substitute for an individual medical evaluation, and nothing here should be read as a recommendation to use BPC-157 for any condition.